Association of β-Amyloid Accumulation with Executive Function in Adults with Unimpaired Cognition
Tideman, Pontus LU ; Stomrud, Erik LU
; Leuzy, Antoine
LU
; Mattsson-Carlgren, Niklas
LU
; Palmqvist, Sebastian
LU
and Hansson, Oskar
LU
(2022)
In Neurology
98(15).
p.1525-1533
- Abstract
Background and Objectives The neuropathologic changes underlying Alzheimer disease (AD) start before overt cognitive symptoms arise, but it is not well-known how they relate to the first subtle cognitive changes. The objective for this study was to examine the independent associations of the AD hallmarks β-amyloid (Aβ), tau, and neurodegeneration with different cognitive domains in cognitively unimpaired (CU) individuals. Methods In this cross-sectional study, CU participants from the prospective BioFINDER-2 study were included. All had CSF biomarkers (Aβ42 and phosphorylated tau [p-tau]181), MRI (cortical thickness of AD-susceptible regions), Aβ-PET (neocortical uptake), tau-PET (entorhinal uptake), and cognitive test data for memory,... (More)
Background and Objectives The neuropathologic changes underlying Alzheimer disease (AD) start before overt cognitive symptoms arise, but it is not well-known how they relate to the first subtle cognitive changes. The objective for this study was to examine the independent associations of the AD hallmarks β-amyloid (Aβ), tau, and neurodegeneration with different cognitive domains in cognitively unimpaired (CU) individuals. Methods In this cross-sectional study, CU participants from the prospective BioFINDER-2 study were included. All had CSF biomarkers (Aβ42 and phosphorylated tau [p-tau]181), MRI (cortical thickness of AD-susceptible regions), Aβ-PET (neocortical uptake), tau-PET (entorhinal uptake), and cognitive test data for memory, executive function, verbal function, and visuospatial function. Multivariable linear regression models were performed using either CSF Aβ42, p-tau181, and cortical thickness or Aβ-PET, tau-PET, and cortical thickness as predictors of cognitive function. The results were validated in an independent cohort (Alzheimer’s Disease Neuroimaging Initiative [ADNI]). Results A total of 316 CU participants were included from the BioFINDER-2 study. Abnormal Aβ status was independently associated with the executive measure, regardless of modality (CSF Aβ42, β = 0.128, p = 0.024; Aβ-PET, β = 0.124, p = 0.049), while tau was independently associated with memory (CSF p-tau181, β = 0.132, p = 0.018; tau-PET, β = 0.189, p = 0.002). Cortical thickness was independently associated with the executive measure and verbal fluency in both models (p = 0.005–0.018). To examine the relationships in the earliest stage of preclinical AD, only participants with normal biomarkers of tau and neurodegeneration were included (n = 217 CSF-based; n = 246 PET-based). Again, Aβ status was associated with executive function (CSF Aβ42, β = 0.189, p = 0.005; Aβ-PET, β = 0.146, p = 0.023), but not with other cognitive domains. The results were overall replicated in the ADNI cohort (n = 361). Discussion These findings suggest that Aβ is independently associated with worse performance on an executive measure but not with memory performance, which instead is associated with tau pathology. This may have implications for early preclinical AD screening and outcome measures in AD trials targeting Aβ pathology.
(Less)
- author
- Tideman, Pontus
LU
; Stomrud, Erik
LU
; Leuzy, Antoine
LU
; Mattsson-Carlgren, Niklas
LU
; Palmqvist, Sebastian
LU
and Hansson, Oskar
LU
- organization
- publishing date
- 2022-04-12
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Neurology
- volume
- 98
- issue
- 15
- pages
- 1525 - 1533
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- scopus:85128488985
- pmid:35022305
- ISSN
- 0028-3878
- DOI
- 10.1212/WNL.0000000000013299
- language
- English
- LU publication?
- yes
- id
- 1379b2dc-db9c-49d6-a11f-34073afdda67
- date added to LUP
- 2022-06-20 16:09:46
- date last changed
- 2024-06-26 03:53:43
@article{1379b2dc-db9c-49d6-a11f-34073afdda67,
abstract = {{<p>Background and Objectives The neuropathologic changes underlying Alzheimer disease (AD) start before overt cognitive symptoms arise, but it is not well-known how they relate to the first subtle cognitive changes. The objective for this study was to examine the independent associations of the AD hallmarks β-amyloid (Aβ), tau, and neurodegeneration with different cognitive domains in cognitively unimpaired (CU) individuals. Methods In this cross-sectional study, CU participants from the prospective BioFINDER-2 study were included. All had CSF biomarkers (Aβ42 and phosphorylated tau [p-tau]181), MRI (cortical thickness of AD-susceptible regions), Aβ-PET (neocortical uptake), tau-PET (entorhinal uptake), and cognitive test data for memory, executive function, verbal function, and visuospatial function. Multivariable linear regression models were performed using either CSF Aβ42, p-tau181, and cortical thickness or Aβ-PET, tau-PET, and cortical thickness as predictors of cognitive function. The results were validated in an independent cohort (Alzheimer’s Disease Neuroimaging Initiative [ADNI]). Results A total of 316 CU participants were included from the BioFINDER-2 study. Abnormal Aβ status was independently associated with the executive measure, regardless of modality (CSF Aβ42, β = 0.128, p = 0.024; Aβ-PET, β = 0.124, p = 0.049), while tau was independently associated with memory (CSF p-tau181, β = 0.132, p = 0.018; tau-PET, β = 0.189, p = 0.002). Cortical thickness was independently associated with the executive measure and verbal fluency in both models (p = 0.005–0.018). To examine the relationships in the earliest stage of preclinical AD, only participants with normal biomarkers of tau and neurodegeneration were included (n = 217 CSF-based; n = 246 PET-based). Again, Aβ status was associated with executive function (CSF Aβ42, β = 0.189, p = 0.005; Aβ-PET, β = 0.146, p = 0.023), but not with other cognitive domains. The results were overall replicated in the ADNI cohort (n = 361). Discussion These findings suggest that Aβ is independently associated with worse performance on an executive measure but not with memory performance, which instead is associated with tau pathology. This may have implications for early preclinical AD screening and outcome measures in AD trials targeting Aβ pathology.</p>}},
author = {{Tideman, Pontus and Stomrud, Erik and Leuzy, Antoine and Mattsson-Carlgren, Niklas and Palmqvist, Sebastian and Hansson, Oskar}},
issn = {{0028-3878}},
language = {{eng}},
month = {{04}},
number = {{15}},
pages = {{1525--1533}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Neurology}},
title = {{Association of β-Amyloid Accumulation with Executive Function in Adults with Unimpaired Cognition}},
url = {{http://dx.doi.org/10.1212/WNL.0000000000013299}},
doi = {{10.1212/WNL.0000000000013299}},
volume = {{98}},
year = {{2022}},
}